Clinical Trials on Sanofi – GSK Vaccine for COVID-19: Update
Combating the Corona virus through various means are underway. Development of COVID Vaccine by prominent pharmaceutical companies are in progress.
The Vaccine (ClinicalTrials.gov Identifier: NCT04537208) being developed in collaboration with Sanofi and GSK has passed the pre-clinical trials and planned to begin its Phase I/II trials in the United States of America. They are expecting that the results will be expected by December 2020. The duo aimed to release the vaccine in the second half of 2021had the trials go smoothly.
The adjuvanted COVID Vaccine was designed to develop using both the companies innovative technology. Sanofi provides the recombinant DNA technology derived S-protein antigen of the SARS-CoV-2 and GSK contributing its adjuvant technology enabling in delivering a greater number of vaccines doses in demand to the pandemic COVID-19.
An adjuvant is added to some vaccines to enhance the immune response and has been shown to create a stronger and longer lasting immunity against infections than the vaccine alone. It can also improve the likelihood of delivering an effective vaccine that can be manufactured at scale.
Look forward with an optimism for a vaccine against COVID in the near future!
